Update on treatment of partial onset epilepsy: role of eslicarbazepine

Markus Rauchenzauner1,2, Gerhard Luef31Department of Pediatrics IV, Medical University Innsbruck, Austria; 2Neuropediatric Department, Sch&ouml;n Klinik Vogtareuth, Vogtareuth, Germany; 3Department of Neurology, Medical University Innsbruck, AustriaAbstract: Partial epilepsy comprises simple...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Markus Rauchenzauner, Gerhard Luef
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/86d10f26a5a84dd8a3ac539a4c665c76
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:86d10f26a5a84dd8a3ac539a4c665c76
record_format	dspace
spelling	oai:doaj.org-article:86d10f26a5a84dd8a3ac539a4c665c762021-12-02T02:01:23ZUpdate on treatment of partial onset epilepsy: role of eslicarbazepine1176-63281178-2021https://doaj.org/article/86d10f26a5a84dd8a3ac539a4c665c762010-11-01T00:00:00Zhttp://www.dovepress.com/update-on-treatment-of-partial-onset-epilepsy-role-of-eslicarbazepine-a5586https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Markus Rauchenzauner1,2, Gerhard Luef31Department of Pediatrics IV, Medical University Innsbruck, Austria; 2Neuropediatric Department, Sch&ouml;n Klinik Vogtareuth, Vogtareuth, Germany; 3Department of Neurology, Medical University Innsbruck, AustriaAbstract: Partial epilepsy comprises simple partial seizures, complex partial seizures, and secondarily generalized seizures, and covers more than 60% of patients with epilepsy. Antiepileptic drugs are generally considered to be the major therapeutic intervention for epilepsy but, despite a broad range of commonly used antiepileptic drugs, approximately 30% of adult patients and approximately 25% of children with epilepsy have inadequate seizure control. Eslicarbazepine acetate (ESL) is a novel voltage-gated sodium channel-blocking agent with presumed good safety and efficacy for adjunctive treatment of patients with drug-resistant partial epilepsy. ESL is a prodrug of eslicarbazepine (the active entity responsible for pharmacologic effects), and is rapidly and extensively hydrolyzed during first pass by liver esterases after oral administration. The half-life of eslicarbazepine at steady-state plasma concentrations is 20&ndash;24 hours, compatible with once-daily administration. ESL 800 mg and 1200 mg significantly reduces seizure frequency and shows a favorable safety profile in adult patients with drug-resistant partial-onset seizures, as demonstrated in previous Phase II and III trials. In children, ESL showed a clear dose-dependent decrease in seizure frequency with good tolerability. The most commonly reported adverse events associated with ESL are dizziness, somnolence, nausea, diplopia, headache, vomiting, blurred vision, vertigo, and fatigue. In conclusion, these characteristics suggest that ESL might be a valid and well tolerated treatment option for patients with drug-resistant partial-onset epilepsy. The convenience of once-daily dosing and a short, simple titration regimen would be of special interest for children, although conclusive published data are lacking to date. Hence, there is an urgent need to establish the therapeutic value of ESL in this special population in the near future.Keywords: eslicarbazepine, partial epilepsy, drug-resistant, antiepileptic drugs Markus RauchenzaunerGerhard LuefDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 723-730 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Markus Rauchenzauner Gerhard Luef Update on treatment of partial onset epilepsy: role of eslicarbazepine
description	Markus Rauchenzauner1,2, Gerhard Luef31Department of Pediatrics IV, Medical University Innsbruck, Austria; 2Neuropediatric Department, Sch&ouml;n Klinik Vogtareuth, Vogtareuth, Germany; 3Department of Neurology, Medical University Innsbruck, AustriaAbstract: Partial epilepsy comprises simple partial seizures, complex partial seizures, and secondarily generalized seizures, and covers more than 60% of patients with epilepsy. Antiepileptic drugs are generally considered to be the major therapeutic intervention for epilepsy but, despite a broad range of commonly used antiepileptic drugs, approximately 30% of adult patients and approximately 25% of children with epilepsy have inadequate seizure control. Eslicarbazepine acetate (ESL) is a novel voltage-gated sodium channel-blocking agent with presumed good safety and efficacy for adjunctive treatment of patients with drug-resistant partial epilepsy. ESL is a prodrug of eslicarbazepine (the active entity responsible for pharmacologic effects), and is rapidly and extensively hydrolyzed during first pass by liver esterases after oral administration. The half-life of eslicarbazepine at steady-state plasma concentrations is 20&ndash;24 hours, compatible with once-daily administration. ESL 800 mg and 1200 mg significantly reduces seizure frequency and shows a favorable safety profile in adult patients with drug-resistant partial-onset seizures, as demonstrated in previous Phase II and III trials. In children, ESL showed a clear dose-dependent decrease in seizure frequency with good tolerability. The most commonly reported adverse events associated with ESL are dizziness, somnolence, nausea, diplopia, headache, vomiting, blurred vision, vertigo, and fatigue. In conclusion, these characteristics suggest that ESL might be a valid and well tolerated treatment option for patients with drug-resistant partial-onset epilepsy. The convenience of once-daily dosing and a short, simple titration regimen would be of special interest for children, although conclusive published data are lacking to date. Hence, there is an urgent need to establish the therapeutic value of ESL in this special population in the near future.Keywords: eslicarbazepine, partial epilepsy, drug-resistant, antiepileptic drugs
format	article
author	Markus Rauchenzauner Gerhard Luef
author_facet	Markus Rauchenzauner Gerhard Luef
author_sort	Markus Rauchenzauner
title	Update on treatment of partial onset epilepsy: role of eslicarbazepine
title_short	Update on treatment of partial onset epilepsy: role of eslicarbazepine
title_full	Update on treatment of partial onset epilepsy: role of eslicarbazepine
title_fullStr	Update on treatment of partial onset epilepsy: role of eslicarbazepine
title_full_unstemmed	Update on treatment of partial onset epilepsy: role of eslicarbazepine
title_sort	update on treatment of partial onset epilepsy: role of eslicarbazepine
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/86d10f26a5a84dd8a3ac539a4c665c76
work_keys_str_mv	AT markusrauchenzauner updateontreatmentofpartialonsetepilepsyroleofeslicarbazepine AT gerhardluef updateontreatmentofpartialonsetepilepsyroleofeslicarbazepine
_version_	1718402789071126528

Update on treatment of partial onset epilepsy: role of eslicarbazepine

Ejemplares similares